Quantcast
Last updated on April 18, 2014 at 0:04 EDT

Latest Nexavar Stories

2014-03-11 04:21:19

WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR(®) (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not...

2013-12-16 08:26:08

Penetration into Tier 2 and Tier 3 Cities of China May Increase Uptake of Targeted Therapies for HCC and Drive Market Growth, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that in China, the uptake of premium-priced targeted therapies for hepatocellular carcinoma (HCC) is heavily influenced by their high cost...

2013-11-22 20:22:37

First and only FDA-approved treatment option for patients with this type of thyroid cancer WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 22, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq:AMGN), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR(®) (sorafenib) tablets for the treatment of patients...

2013-09-17 08:31:58

WHIPPANY, N.J., Sept. 17, 2013 /PRNewswire/ -- Bayer HealthCare announced today that data from the company's oncology portfolio, including Nexavar(®) (sorafenib) tablets, Stivarga(®) (regorafenib) tablets and Xofigo(®) (radium Ra 223 dichloride) injection will be presented at the 2013 European Cancer Congress (ECCO/ESMO/ESTRO), September 28 - October 1, in Amsterdam, Netherlands. These data include an oral presentation of a subanalysis from the Phase III trial of sorafenib in patients...

2013-08-27 04:21:04

WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., Aug. 27, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals (NASDAQ: ONXX) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation to the supplemental New Drug Application (sNDA) for the oral multi-kinase inhibitor Nexavar(®) (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid...

2013-07-08 12:28:38

DUBLIN, July 8, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/b2njt5/liver_cancer) has announced the addition of the "Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail" [http://www.researchandmarkets.com/research/b2njt5/liver_cancer ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769...

2013-07-01 04:20:38

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., July 1, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals (NASDAQ: ONXX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and an application for marketing authorization to the European Medicines Agency (EMA) for the oral multi-kinase inhibitor Nexavar(® )(sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine...

2013-06-02 08:20:08

Data to be Presented at Plenary Session at Annual Meeting of the American Society of Clinical Oncology WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., June 2, 2013 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive results from the Phase 3 DECISION trial investigating the use of Nexavar(®) (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated...

2013-05-15 20:23:09

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 - June 4, in Chicago, IL (USA). These...

2013-05-15 04:21:12

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga(®) (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on Nexavar(®) (sorafenib) tablets, an anticancer medicine for the treatment of patients with...